You are here

Article Text

Article menu

Download PDFPDF

Cervical cancer
2022-RA-443-ESGO Lymph node involvement in early-stage cervical cancer: is the lymphangiogenesis a risk factor? Results of MICROCOL study
Free
  1. Matteo Tantari1,
  2. Stefano Bogliolo2,
  3. Matteo Morotti3,
  4. Vincent Balaya4,
  5. Florent Boutitie5,
  6. Annie Buenerd6,
  7. Laurent Magaud7,
  8. Fabrice Lécuru8,
  9. Benedetta Guani9 and
  10. Patrice Mathevet9
  1. 1Gynecology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  2. 2Department of Obstetrics and Gynecological Oncology, ‘P.O del Tigullio’ Hospital-ASL4, Metropolitan area of Genoa, Lavagna, Italy
  3. 3Centre Hopital-Universitaire Vaudois, Lausanne, Switzerland
  4. 4Department of Gynecology and Obstetrics, Foch Hospital, Suresnes, Paris, France
  5. 5Department of Biostatistics, University Hospital of Lyon, Lyon, France
  6. 6Department of Pathology, Hospices Civils de Lyon HCL, Lyon, France
  7. 7Clinical Research and Epidemiology Department, Hospices Civils de Lyon, Lyon, France
  8. 8Institut Curie, Paris, France
  9. 9Department of Gynecology and Obstetrics, Centre Hopital-Universitaire Vaudois, Lausanne, Switzerland

Abstract

Introduction/Background In patients with cervical cancer, the presence of tumoral lymph-vascular space invasion (LVSI) is the main risk factor for pelvic lymph node metastasis (PLNM). The objective of this study was to evaluate the presence of several markers of lymphangiogenesis in early-stage cervical cancer and their correlation with PLNM and tumoral recurrence.

Methodology Patients with early-stage cervical carcinoma underwent sentinel lymph node (SLN) sampling in association with complete pelvic lymph node dissection. Primary tumors were stained with the following markers: Ki67, D2–40, CD31 and VEGF-C. A 3 years follow-up was performed to evaluate the disease-free survival.

Results Overall, 14 patients (18.6%) had PLNM. Positive LVSI was seen in 29 patients (38.6%). There was a significant correlation between LVSI evidenced by H/E staining and PLNM (p<0.001). There was no correlation between high Ki67, CD31, D2–40, and VEGF-C staining with PLNM or tumor recurrence.

View this table:
Abstract 2022-RA-443-ESGO Table 1

Correlation between proliferation markers and lymph node involvement

Abstract 2022-RA-443-ESGO Figure 1
Abstract 2022-RA-443-ESGO Figure 1

Cytoplasmic VEGF-C antibody staining

Conclusion Our data support lymphatic spread does not require the proliferation of new lymphatic endothelial cells in early-stage cervical cancer. These results emphasize the importance of pre-existing peritumoral lymphatic vessels in the metastatic process in early cervical cancer. None of the markers of lymphangiogenesis and proliferation assessed in this study were predictive of PLNM or recurrence.

https://doi.org/10.1136/ijgc-2022-ESGO.25

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.